Why Pulse Biosciences is on investors’ radar

Pulse Biosciences (PLSE) has drawn fresh attention after a period of strong share price moves, including gains over the past month and past 3 months that stand out against its recent trading history.

Against this backdrop, the recent 32.76% 30-day share price return and 30.23% 90-day share price return sit alongside an 89.17% year-to-date share price gain and a 3-year total shareholder return of 258.27%. Together, these figures point to strong momentum rather than a short-term spike.

If you are looking beyond Pulse Biosciences for stocks with a similar high-growth angle in healthcare technology, it is worth scanning 39 healthcare AI stocks.

With the stock up strongly this year and trading at $25.33 against an analyst price target of $30.67, the key question is simple: Is there still value on the table here, or is the market already pricing in future growth?

Most Popular Narrative: 15.6% Undervalued

Pulse Biosciences’ most followed narrative pegs fair value at $30.00, which sits above the last close at $25.33, and frames the recent share price strength in a longer term context.

A focused commercial model that targets key accounts in a few large metropolitan areas, along with positive reimbursement trends for Vybrance procedures, is aimed at driving higher account utilization and improving gross margins as disposables and full system sales scale relative to current GAAP net loss of US$19.4 million.

Want to see what is behind this valuation gap? The narrative leans heavily on rapid revenue expansion, margin repair and a future earnings multiple that assumes strong adoption. The exact mix of those ingredients is where the story gets interesting.

Result: Fair Value of $30.00 (UNDERVALUED)

However, the bullish story still hinges on very early Vybrance revenues against heavy quarterly losses and on multi year cardiac trials that could face delays or setbacks.

Another way to look at Pulse Biosciences’ value

The bullish narrative leans on future earnings and growth assumptions, but the current P/B ratio of 26.4x versus 2.4x for the US Medical Equipment industry and 6.8x for peers points to a rich valuation. If sentiment cools, a shift toward those lower benchmarks could pressure the share price.

Next Steps

Mixed messages or a clear setup, either way this is a moment to move quickly, review the numbers yourself, and weigh up the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that better fit your goals, risk comfort, and timeline across different sectors and styles.

• Target potential mispricings by scanning companies that screen as high quality yet priced below their estimated worth using the 48 high quality undervalued stocks.
• Strengthen your income focus by checking stocks that combine robust yields with resilient business profiles through the 10 dividend fortresses.
• Prioritize resilience by reviewing companies with comparatively lower risk scores and steadier profiles using the 63 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.